Ganoderma lucidum triterpenoid compound as well as preparation method and application thereof

By extracting and preparing the neutral Ganoderma lucidum triterpene compound norchizhiol A from the red zirconium, the problem of difficult inhibition of adipocyte proliferation and differentiation in the prior art is solved, and the regulation of blood lipid levels and the improvement of lipoprotein distribution in obese mice is achieved. Effective anti-obesity and lipid-lowering drugs.

CN118978561AActive Publication Date: 2024-11-19GUANGXI UNIV OF CHINESE MEDICINE
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411059100.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-19
Estimated Expiration
2044-08-02

AI Technical Summary

Technical Problem

The prior art is difficult to effectively inhibit the proliferation and differentiation of adipocytes, which leads to difficult control of obesity problems and lacks effective lipid-lowering and anti-obesity drugs.

Method used

By extracting and preparing a neutral Ganoderma triterpene compound norchizhiol A from the red zirconium, effective lipid-lowering and anti-obesity-resistant using ethanol soaking, acid saline solution extraction, silica gel column chromatography separation and Sephadex LH20 gel purification, it is prepared by using steps such as ethanol soaking, and lipid-lowering and anti-obesity. drug.

Benefits of technology

norchizhiol A significantly inhibits the accumulation and differentiation of triglycerides in pre-adipocytes of 3T3-L1, regulates the blood lipid levels of obese mice, effectively intervenes to improve lipoprotein distribution, and is used to prepare anti-obesity, lipid and glucose-lowering medicines and health care products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978561A_ABST
    Figure CN118978561A_ABST
Patent Text Reader

Abstract

The invention discloses a dalbergia wood triterpenoid compound as well as a preparation method and application thereof. The dalbergia wood triterpenoid compound norchizhiol A can be quickly prepared from ganoderma lucidum. Experiments prove that the norchizhiol A can be used for inhibiting the accumulation of triglyceride in the differentiation process of 3T3-L1 preadipocytes. The norchizhiol A also effectively reduces the weight gain and liver coefficient of obese mice induced by high fat diet, regulates the blood fat level of the obese mice, and remarkably intervenes and improves the lipoprotein distribution of organisms. The compound can be used for preparing anti-obesity and lipid-lowering medicines and health-care products, functional foods and food additives.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of natural product chemistry, and in particular to a ganoderma lucidum triterpene compound and a preparation method and application thereof. Background Art

[0002] Ganoderma lucidum is a traditional precious Chinese medicinal material with high medicinal value. It has a good regulatory effect on the human nervous, immune, cardiovascular and other systems, and is widely used in health foods, medicines, and cosmetics. Ganoderma lucidum is rich in a variety of chemical components, including Ganoderma lucidum polysaccharides, Ganoderma lucidum triterpenoids, amino acids, proteins, sterols, etc. Ganoderma lucidum triterpenoids are also one of the key functional ingredients in Ganoderma lucidum. Ganoderma lucidum triterpenoids have a complex chemical structure, a wide variety, and high fat solubility. They have antioxidant, liver protection, anti-tumor, anti-inflammatory, immune enhancement, and lowering blood lipids and blood sugar. In recent years, neutral triterpenes have become a hot spot in Ganoderma lucidum research.

[0003] Obesity has become an important public health issue worldwide. Globally, the prevalence of obesity is showing an upward trend. Obesity is closely related to a variety of chronic diseases, such as diabetes, cardiovascular disease, myocardial infarction, hypertension, and hyperlipidemia. These diseases not only reduce the quality of life of patients, seriously threaten personal health, increase the risk of premature death, but also bring a huge burden to the healthcare system.

[0004] Obesity is the result of the destruction of the balance between energy intake and consumption. Excessive excess energy is stored in adipocytes in the form of triglycerides, causing the adipocytes to gradually grow larger. When the adipocyte volume reaches a certain level, new pre-adipocytes will continue to proliferate to prepare for the storage of triglycerides, which ultimately leads to the continuous enlargement of adipose tissue and the continuous increase in body weight. At present, inhibiting the proliferation of adipocytes, the proliferation and differentiation of pre-adipocytes are important ideas for anti-obesity. Fat accumulation is a key step in the development of obesity. Controlling this step will effectively control the progression of obesity, and the core process of obesity pathophysiology is excessive fat deposition. 3T3-L1 pre-adipocytes induce fat accumulation in vitro and differentiate into mature adipocytes. It is currently recognized as a cell line for studying the process of fat deposition in the country and is widely used in the study of drug lipid-lowering and anti-obesity activity mechanisms. Diet-induced obese mouse models are also common animal models for obesity research. By giving mice a high-calorie, high-fat diet for a long time, they are induced to become obese by simulating the bad eating habits of humans. This model can better reflect the role of dietary factors in the occurrence of obesity. Using the obese mouse model, scientists have a deeper understanding of the physiological and pathological mechanisms of obesity. Obese mouse models play a key role in drug development. Before new weight loss drugs enter clinical trials, they are usually tested on obese mice to evaluate their efficacy and safety. Summary of the invention

[0005] The purpose of the present invention is to provide a triterpene compound of Ganoderma lucidum to address the technical defects in the prior art.

[0006] Another object of the present invention is to provide a method for preparing the triterpene compounds of Ganoderma lucidum.

[0007] Another object of the present invention is to provide the application of the triterpene compounds of Ganoderma lucidum.

[0008] The technical solution adopted to achieve the purpose of the present invention is:

[0009] A triterpene compound of Ganoderma lucidum, the structural formula of which is shown in formula (I):

[0010]

[0011] The norlingzhi triterpenoid compound is a neutral ganoderma triterpenoid.

[0012] Another aspect of the present invention also includes a method for preparing the triterpenoid compound of Ganoderma lucidum, comprising the following steps:

[0013] Step 1, soaking the crushed Ganoderma lucidum (Leyss. ex Fr.) Karst in ethanol to obtain a Ganoderma lucidum extract;

[0014] Step 2, suspending the Ganoderma lucidum extract obtained in step 1 with an acidic saline solution, extracting with ethyl acetate, and recovering the solvent to obtain an ethyl acetate extract;

[0015] Step 3, using dichloromethane-methanol solution as the mobile phase, separating the ethyl acetate extract obtained in step 2 by silica gel column chromatography, combining the fractions according to TLC analysis to obtain 5 components Fr.1 to Fr.5; purifying component Fr.2 by ODS column, and gradient eluting with methanol-water solution to obtain 7 components Fr.2.1 to Fr.2.7; Fr.2.4 is purified by Sephadex LH20 gel, and then separated by preparative liquid phase, and eluted with acetonitrile-water solution as the mobile phase to obtain the Ganoderma lucidum triterpene compound.

[0016] In the above technical solution, in step 1, the ethanol concentration is 75-95 v / v%.

[0017] In the above technical solution, in step 2, the acidic salt solution is a saturated aqueous solution of NaHCO3 or KHCO3.

[0018] In the above technical solution, in step 3, the volume ratio of dichloromethane to methanol in the dichloromethane-methanol solution is 100:0 to 0:100.

[0019] In the above technical solution, in step 3, the volume ratio of methanol to water in the methanol-water solution is 20:80 to 100:0.

[0020] In the above technical solution, in step 3, when Fr.2.4 is purified by Sephadex LH20 gel, the mobile phase used is methanol-chloroform solution or acetone, and the volume ratio of methanol to chloroform in the methanol-chloroform solution is 100:0 to 20:80.

[0021] In the above technical solution, in step 3, the volume ratio of acetonitrile to water in the acetonitrile-water solution is 30:70 to 80:20.

[0022] Another aspect of the present invention also includes the use of the triterpenoid compounds of Ganoderma lucidum in the preparation of lipid-lowering or anti-obesity drugs, health products, functional foods and / or food additives.

[0023] Another aspect of the present invention also includes a lipid-lowering or anti-obesity drug, comprising an active ingredient and a pharmaceutically acceptable excipient or carrier, wherein the active ingredient includes the Ganoderma lucidum triterpene compound.

[0024] Compared with the prior art, the present invention has the following beneficial effects:

[0025] 1. The present invention discloses a method for preparing norchizhiol A from Ganoderma lucidum, which can simply, effectively and quickly obtain a large amount of norchizhiol triterpenoid compounds.

[0026] 2. The present invention discloses that norchizhiol A, a triterpenoid compound of Ganoderma lucidum, inhibits the accumulation of triglycerides in the process of differentiation of 3T3-L1 preadipocytes, effectively regulates the blood lipid level of obese mice, and significantly intervenes to improve the lipoprotein distribution of mice. The triterpenoid compound of Ganoderma lucidum, norchizhiol A, can be used to prepare medicines and health products, functional foods, and food additives for anti-obesity, lipid-lowering and blood sugar-lowering. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 H NMR spectrum of the compound;

[0028] Figure 2 C NMR spectrum of compounds;

[0029] Figure 3 HSQC spectrum of the compound;

[0030] Figure 4 HMBC spectrum of compounds;

[0031] Figure 5 Compound 1 H- 1H COSY spectrum;

[0032] Figure 6 NOESY spectrum of compounds;

[0033] Figure 7 The compounds inhibited the proliferation of 3T3-L1 preadipocytes;

[0034] Figure 8 Dose-effect curve of the compound inhibiting 3T3-L1 preadipocyte differentiation;

[0035] Fig. 9 Effects of different concentrations of compounds on weight gain in obese mice;

[0036] Fig.10 Effects of different concentrations of compounds on liver coefficients of obese mice;

[0037] Fig.11 Effects of different concentrations of compounds on total cholesterol in obese mice;

[0038] Fig.12 Effects of different concentrations of compounds on triglycerides in obese mice;

[0039] Fig.13 Effects of different concentrations of compounds on low-density lipoprotein cholesterol in obese mice;

[0040] Fig.14 Effects of different concentrations of compounds on high-density lipoprotein cholesterol in obese mice. DETAILED DESCRIPTION

[0041] The present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0042] Example 1

[0043] The preparation method of the triterpenoid compound of Ganoderma lucidum comprises the following steps:

[0044] Step 1, extracting extract: Ganoderma lucidum (Leyss.ex Fr.) Karst is crushed by a grinder, and soaked in 15 times the volume of 95% ethanol, each time for 7 days, for a total of 4 times. The extracts are combined, the ethanol is recovered under reduced pressure, and concentrated to obtain an extract.

[0045] Step 2, preparation of the neutral part: dissolving the extract obtained in step 1 with a saturated sodium bicarbonate aqueous solution, extracting with 1-2 times the volume of ethyl acetate, extracting three times in total, combining the ethyl acetate extracts, recovering the ethyl acetate under reduced pressure, and concentrating to obtain the neutral part.

[0046] Step 3, separation of compounds: The neutral part obtained in step 2 was separated by silica gel column chromatography, with dichloromethane-methanol (100:0-0:100, V / V) as the mobile phase, and the fractions were combined according to TLC analysis to obtain 5 components (Fr.1-Fr.5). Fr.2 was purified by ODS column, with methanol-water (20:80-100:0, V / V) gradient elution to obtain 7 components (Fr.2.1-Fr.2.7). Fr.2.4 was purified by Sephadex LH-20 column, with methanol as the mobile phase. The Fr.2.4 component was then separated by preparative liquid phase, with acetonitrile-water (45:55, V / V) as the mobile phase to obtain the compound.

[0047] The structural formula of the triterpenoid compound of Ganoderma lucidum is as follows (1):

[0048]

[0049] The triterpenoids of Ganoderma lucidum are white powder. HRESIMS molecular ion peak m / z 441.3000 [M+Na] + (calcd.for C 26 H 42 O4Na,441.2981), combined 1 H-NMR spectrum and 13 C-NMR spectrum, molecular formula is C 26 H 42 O4. Based on the infrared and ultraviolet spectra, it is speculated that the compound contains hydroxyl groups (3420cm -1 ) and α,β-unsaturated ketones (1688cm -1 and 257nm). 1 HNMR spectrum, 13C NMR combined with HSQC spectrum showed that the compound contained 26 carbon signals, including 6 methyl carbons, 8 methylene carbons (one of which contained oxygen-containing methylene), 5 methine carbons (including 2 oxygen-containing methine delta C 77.9 and 71.9), 4 sp 3 The above NMR signals of this compound are similar to those of ganosineniol A, but it has one less oxygen-containing methine and one more methylene. H 2.96and 2.82) and C-8(δ C 166.1) and C-9 (δ C 139.4)HMBC related signals, and H-7(δ H 2.96and 2.82) and H-6(δ H 1.49) COSY related signals indicate that the 7-position is a methylene group. H4.53) and H-22(δ H 1.91) indicates that there is one more methylene group on the side chain at C17 than ganosineniol A. H 3.19) and H-28(δ H 1.03) and H-5(δ H 0.87), and H-18 (δ H 0.83) and H-15(δ H 4.33) The key ROESY related signals infer that 3-OH and 15-OH are β- and α-oriented, respectively. According to the biogenic relationship of Ganoderma lucidum triterpenes, the compound is inferred to be 3S, 10S, 13R, 14R, 15S, 17R. The structure of the compound is identified as (3S, 10S, 13R, 14R, 15S, 17R)-3, 15-dihydroxy-17-(4-hydroxybutan-2-yl)-4, 4, 10, 13, 14-pentamethyl-1, 2, 3, 4, 5, 6, 7, 10, 12, 13, 14, 15, 16, 17-tetradecahydro-11H-cyclopenta[a]phenanthren-11-one, commonly known as norchizhiol A.

[0050] Example 2

[0051] Verification of the inhibitory effect of triterpenoids from Ganoderma lucidum on the proliferation of 3T3-L1 preadipocytes.

[0052] 3T3-L1 cells were cultured in complete medium (90% DMEM high glucose medium, 10% fetal bovine serum) in an incubator until the logarithmic growth phase, digested, and inoculated into 96-well culture plates at a density of 5×10 3 / well. Cultured in a 37°C CO2 incubator for 24 hours. After the cells adhered, replaced with DMEM complete culture medium containing different concentrations of the compound and continued to culture, so that the final concentration of the compound norchizhiol A was 20, 40, 80, 160, and 320 μg / mL, respectively. The control group was a DMEM complete culture medium without the compound, and the blank group was a complete culture medium with an equal volume (without preadipocytes 3T3-L1 and compounds). Each group has 3 replicate wells. After 48 hours, the culture medium was discarded, 100 μL of the prepared MTT reagent was added, and the cells were placed in an incubator for incubation for 4 hours. The absorbance value (OD value) of each group was measured at a wavelength of 450 nm, and the survival rate was calculated. The results are as follows Figure 7As shown, the compound had no significant proliferation inhibitory effect on preadipocytes 3T3-L1 at a concentration below 160 μg / mL, and had a weaker proliferation inhibitory effect on preadipocytes 3T3-L1 at a concentration of 320 μg / mL.

[0053] Example 3

[0054] Verification of the inhibitory activity of triterpenoids from Ganoderma lucidum on differentiation of 3T3-L1 preadipocytes

[0055] The compound to be tested was prepared into a 1mg / mL stock solution with DMSO, and diluted into working solutions of different concentrations during the test; 0.1% DMSO was used as a blank control, and berberine was used as a positive control. Adipocytes 3T3-L1 in the logarithmic growth phase were inoculated in a 48-well plate. After the cells were completely fused, differentiation induction medium I (DMEM medium supplemented with 10% fetal bovine serum, 100U / mL penicillin, 100μg / mL streptomycin, 10μg / mL insulin, 1μM dexamethasone, 0.5mM 3-isobutyl-1-methylxanthine and 10ng / mL biotin) was added, and a certain concentration of compound was added at the same time. No compound was added to the blank control. After 48h of culture, differentiation induction medium II (DMEM complete medium containing 10μg / mL insulin) was used to continue culture for 72h, and the compound to be tested was added. The culture medium was removed, the cells were washed twice with PBS, and fixed with 10% formalin for 30min. The fixative was discarded and Oil Red O was stained for 15min. The morphology and lipid droplets of adipocytes were observed under an inverted microscope, the stained cells were treated with isopropanol, and the OD value at 490nm was measured to quantify the degree of differentiation.

[0056] like Figure 8 As shown in the results, the compound norchizhiol A can inhibit the differentiation of 3T3-L1 cells to varying degrees at a concentration of 10-160 μg / mL and form a certain dose-effect relationship, with an IC50 value of 32.9 μg / mL. The IC50 value of the positive drug berberine is 47.9 μg / mL. Compared with the positive drugs, the compound norchizhiol A has the activity of inhibiting the differentiation of 3T3-L1 preadipocytes.

[0057] Example 4

[0058] Experiment on the improvement of triterpenoids of Ganoderma lucidum on obese mice

[0059] Four-week-old C57BL / 6J male mice were raised in an animal room with a temperature of 25℃ and a 12-h light-dark cycle, and were adaptively fed for 7 days. They were randomly divided into 4 groups, normal control group (CK), model group (MODEL), low-dose drug group (GL) and high-dose drug group (GH), with 8 mice in each group. The CK group was fed with a basic diet, and the MODEL, GL and GH groups were fed with a high-fat diet. After 16 weeks of feeding, the average body weight of mice in the model group and drug group exceeded 20% of the average body weight of the normal control group. The CK and MODEL groups were intraperitoneally injected with 5mL / kg of normal saline once a day, the GL group was intraperitoneally injected with 2mg / kg of the compound norchizhiol A solution once a day, and the GH group was intraperitoneally injected with 20mg / kg of norchizhiol A solution once a day. The intervention treatment time was 8 weeks.

[0060] The weight of mice was measured weekly, and the amount of water and feed consumed by mice was recorded. After the last intervention, the mice were fasted for 12 hours and weighed. After the mice were killed, the livers of mice in each group were dissected and taken out, and their weights were measured to calculate the liver index. After 8 weeks of norchizhiol A intervention, the weight gain of mice in each group was as follows: Fig. 9 As shown in the figure, the weight gain of mice in the MODEL group was 14.20 g, which was significantly higher than that of mice in the CK group (P<0.01). Compared with the MODEL group, the weight gain of mice in the GL group (12.51±0.75 g) was slightly decreased, but there was no significant difference (P>0.05), while the weight gain of mice in the GH group (7.22±0.45 g) was significantly lower than that in the MODEL group (P<0.01). Fig.10 As shown, there was a very significant difference in the liver index of mice between the MODEL group (6.53%) and the CK group (3.93%) (P<0.01). Compared with the MODEL, the liver index of mice in the GL group (5.98%) decreased, with a significant difference (P<0.05), and the liver index of mice in the GH group (3.94%) was significantly lower than that in the MODEL group (P<0.01). After intervention with the compound norchizhiol A, the weight gain and liver fat of obese mice were inhibited to varying degrees, especially the high concentration of the compound norchizhiol A, which was similar to the blank control group, with no significant difference (P>0.05). The compound norchizhiol A can effectively reduce the weight gain and liver index of obese mice induced by a high-fat diet.

[0061] After 8 weeks of intervention with the compound norchizhiol A, mice in each group were fasted for 12 hours. After anesthesia with sodium pentobarbital, blood was collected by removing the eyeballs and placed in an EP tube containing an anticoagulant. After standing for 1 hour, the blood was centrifuged at 3000r / min for 10 minutes to collect the supernatant. An automatic biochemical analyzer was used to detect total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in serum. Fig.11 , 12 As shown in Figures 13 and 14, compared with the CK group, the levels of TC, TG and LDL-C in the MODEL group were significantly increased (P<0.05), and the level of HDL-C was significantly decreased (P<0.05); the serum TC of the MODEL group mice increased by 0.99 times, TG increased by 1.25 times, LDL-C increased by 1.59 times, and HDL-C decreased by 0.89 times. Compared with the MODEL group, the serum TC levels of the GL and GH group mice were significantly decreased (P<0.05), decreased by 16.76% and 46.91%, respectively. Fig.12 It can be seen that the serum TG levels of mice in the GL group and GH group were reduced by 19.61% and 54.31% respectively compared with those in the CK group. Fig.13 and 14 It can be seen that the serum LDL-C levels of mice in the GL group and GH group were reduced by 10.30% and 58.39% respectively compared with the CK group. In addition, compared with the CK group, the HDL-C levels of the GL group and GH group were significantly increased (P<0.05), increased by 23.61% and 83.26% respectively. This shows that different doses of norchizhiol A can effectively regulate the blood lipid levels of obese mice, with a dose-dependent relationship. Among them, high doses of norchizhiol A can significantly intervene and improve the body's lipoprotein distribution.

[0062] The above is only a preferred embodiment of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A triterpene compound of Ganoderma lucidum, characterized in that: The structural formula is shown in formula (I):

2. The method for preparing the triterpenoid compound of Ganoderma lucidum according to claim 1, characterized in that: The following steps are involved: Step 1, soaking the crushed Ganoderma lucidum (Leyss. ex Fr.) Karst in ethanol to obtain a Ganoderma lucidum extract; Step 2, suspending the Ganoderma lucidum extract obtained in step 1 with an acidic saline solution, extracting with ethyl acetate, and recovering the solvent to obtain an ethyl acetate extract; Step 3, using dichloromethane-methanol solution as the mobile phase, separating the ethyl acetate extract obtained in step 2 by silica gel column chromatography, combining the fractions according to TLC analysis to obtain 5 components Fr.1 to Fr.5; purifying component Fr.2 by ODS column, and gradient eluting with methanol-water solution to obtain 7 components Fr.2.1 to Fr.2.7; Fr.2.4 is purified by Sephadex LH20 gel, and then separated by preparative liquid phase, and eluted with acetonitrile-water solution as the mobile phase to obtain the Ganoderma lucidum triterpene compound.

3. The preparation method according to claim 2, characterized in that: In the step 1, the ethanol concentration is 75-95 v / v%.

4. The preparation method according to claim 2, characterized in that: In step 2, the acidic salt solution is a saturated aqueous solution of NaHCO3 or KHCO3.

5. The preparation method according to claim 2, characterized in that: In the step 3, in the dichloromethane-methanol solution, the volume ratio of dichloromethane to methanol is 100:0 to 0:

100.

6. The preparation method according to claim 2, characterized in that: In the step 3, the volume ratio of methanol to water in the methanol-water solution is 20:80 to 100:

0.

7. The preparation method according to claim 2, characterized in that: In the step 3, when Fr.2.4 is purified by Sephadex LH20 gel, the mobile phase used is a methanol-chloroform solution or acetone, and the volume ratio of methanol to chloroform in the methanol-chloroform solution is 100:0 to 20:

80.

8. The preparation method according to claim 2, characterized in that: In the step 3, the volume ratio of acetonitrile to water in the acetonitrile-water solution is 30:70 to 80:

20.

9. Use of the triterpenoid compound of Ganoderma lucidum as claimed in claim 1 in the preparation of lipid-lowering or anti-obesity drugs, health products, functional foods and / or food additives.

10. A lipid-lowering or anti-obesity drug, characterized in that: It comprises an active ingredient and a pharmaceutically acceptable auxiliary material or carrier, wherein the active ingredient comprises the triterpene compound of Ganoderma lucidum as claimed in claim 1.

Citation Information

Patent Citations

  • Novel triterpenoid compound, preparation method and medical application thereof

    CN105037470A

  • Nortriterpenoid compound with neuroprotective effect as well as preparation method and application of nortriterpenoid compound

    CN117362377A